Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN Pre-Tax Margin

Income before tax as a percentage of revenue.

Repligen CorporationNASDAQ: RGEN

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to 6.9%

Pre-tax margin was 6.9% in Q2 FY2026, down 3.1 pp from a year earlier. On a trailing-twelve-month basis it was 6.6%, up 8.7 pp year over year. Over 3 fiscal years it narrowed by 18.9 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
6.9%+6.0 pp QoQ
Last fiscal yearDec 2025
8.5%+12.7 pp YoY
LTMJun 2026
6.6%+8.7 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.1 pp——
1 year+12.7 pp——
3 years-18.9 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
8.5%
Year-over-year change
+12.7pp

Pre-Tax Margin vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 pre-tax margin of 6.6% is the 6th highest of the 9 companies compared; the peer median is 15.1%.
  • Its year-over-year change of +8.7 pp is the 3rd highest of 9, against a peer median of +1.1 pp.
  • Over three fiscal years its change of -18.9 pp compares with a peer median of -3.8 pp.
RGEN Competitors Peer median
Pre-Tax Margin for RGEN and competitors
Company Period LTM level YoY 3-year change
AAgilent Technologies, Inc.LTM Jul 202622.5% +2.0 pp-1.3 pp
QGENQiagen N.V.LTM Jun 202622.0% -2.0 pp-0.5 pp
TECHBio-Techne CorporationLTM Sep 202618.5% +9.8 pp-10.0 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202616.6% +0.3 pp-0.8 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202613.5% -4.1 pp+206.4 pp
RGENRepligen CorporationLTM Jun 20266.6% +8.7 pp-18.9 pp
AVTRAvantor, Inc.LTM Jun 2026-7.2% -19.6 pp-18.1 pp
BLFSBioLife Solutions, Inc.LTM Mar 2026-10.4% +1.8 pp-6.2 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-65.4% +96.3 pp-189.0 pp
Peer median (excluding RGEN) 15.1%+1.1 pp-3.8 pp

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue670.53M801.54M632.36M634.44M738.26M
Cost of Revenue279.28M345.83M353.92M359.79M390.63M
Gross Profit391.25M455.71M278.44M274.65M347.62M
Gross Margin58.3%56.9%44.0%43.3%47.1%
Research & Development34.27M43.94M42.72M43.2M54.18M
Selling, General & Admin183.87M215.83M218.58M263.37M290.51M
Operating Expenses224.01M231.04M230.74M309.76M288.05M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
EBITDA203.27M277.31M145.32M80.26M182.51M
EBITDA Margin30.3%34.6%23.0%12.7%24.7%
Operating Income167.25M224.67M47.7M(35.11M)59.58M
Operating Margin24.9%28.0%7.5%-5.5%8.1%
Interest Income176K6.98M0027.57M
Interest Expense12.71M2.98M10.03M22.57M23.17M
Other Income / Expenses(13.71M)(5.53M)9M8.08M2.81M
Income Before Tax153.54M219.14M56.71M(27.04M)62.38M
Pre-Tax Margin22.9%27.3%9.0%-4.3%8.5%
Income Tax Expense25.25M33.18M21.11M(1.52M)13.49M
Net Income128.29M185.96M35.6M(25.51M)48.89M
Net Margin19.1%23.2%5.6%-4.0%6.6%
EPS (Basic)2.333.350.64(0.46)0.87
EPS (Diluted)2.243.240.63(0.46)0.86
Weighted Avg Shares55.02M55.46M55.72M55.94M56.23M
Weighted Avg Shares (Diluted)57.26M57.46M56.38M55.94M56.56M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.